Print Page | Sign In | Join
Business Wire Life Sciences News (US)
Share |

Cystic Fibrosis Foundation Commits $100 Million to Infection ResearchOpen in a New Window

BETHESDA, Md.--(BUSINESS WIRE)--The Cystic Fibrosis Foundation announced today that it will commit at least $100 million over the next five years as part of a sweeping effort to address the chronic and intractable infections that are a hallmark of cystic fibrosis (CF). The Infection Research Initiative is a comprehensive approach to improve outcomes associated with infections through enhanced detection, diagnosis, prevention, and treatment. “Infection is a leading cause of loss of lung function

 

Former DEA Agent and Inspiration for Netflix's Narcos Series Announced as Verde Technologies' Newest Advisory Council MemberOpen in a New Window

MINNETONKA, Minn.--(BUSINESS WIRE)--#Deterra--FORMER DEA AGENT AND INSPIRATION FOR NETFLIX'S NARCOS SERIES ANNOUNCED AS VERDE TECHNOLOGIES' NEWEST ADVISORY COUNCIL MEMBER

 

Singularity University’s Exponential Medicine Shapes the Future of Healthcare, Showcases Advances in Healthcare TechnologiesOpen in a New Window

SAN DIEGO--(BUSINESS WIRE)--#xMed--Experts in healthcare, technology and more will convene for Singularity University's eighth annual Exponential Medicine, Nov. 4-7 in San Diego.

 

ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2018 Operating ResultsOpen in a New Window

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Company will host a conference call at 8:00 a.m. ET on Friday, November 2, 2018 to discuss its third quarter operating results. Management will also provide a brief update on the business. Conference Call InformationTo access the live call by phone, dial 323-794-2423; the conference ID is 8582527. The call may also

 

CORRECTING and REPLACING Remedy Launches AI-Powered Healthcare Screening Service to Find Millions of Patients With Undiagnosed Chronic DiseaseOpen in a New Window

SAN FRANCISCO--(BUSINESS WIRE)--Remedy launched Remedy Sentinel, a new AI-powered service to identify patients with undiagnosed chronic illnesses.

 

Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial ResultsOpen in a New Window

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will host a conference call and webcast on Nov. 1, to review its financial results for the third quarter and nine months 2018.

 

Revance Therapeutics to Release Third Quarter 2018 Financial Results on Thursday, November 1, 2018Open in a New Window

NEWARK, Calif.--(BUSINESS WIRE)--Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the Company will release second quarter 2018 financial results on Thursday, November 1, 2018 after the close of market. Revance will host a corresponding conference call and a live webcast at 1:30pm PT/4:30pm ET on the same day to discuss the results and provide a business and pipeline update.

 

Verastem Oncology Announces Executive Leadership Appointments and ChangesOpen in a New Window

BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq: VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced the appointment of Ironwood Pharmaceuticals, Inc.’s Chief Financial Officer Gina Consylman to its Board of Directors. Ms. Consylman, who will also serve as the Chair of the Board’s Audit Committee, replaces Louise Phanstiel who is leaving the Board to pursue other professiona

 

Exelixis to Release Third Quarter 2018 Financial Results on Thursday, November 1, 2018Open in a New Window

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ: EXEL) announced today that its third quarter 2018 financial results will be released on Thursday, November 1, 2018 after the markets close. At 5:00 p.m. EDT / 2:00 p.m. PDT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via the Internet from the company’s website. To access the webcast link, log onto www.exelixis.com and proceed t

 

CONMED Corporation to Announce Third Quarter 2018 Financial Results on November 1, 2018Open in a New Window

UTICA, N.Y.--(BUSINESS WIRE)--CONMED Corporation (NASDAQ:CNMD) today announced that it will report financial results for the third quarter of fiscal year 2018 after the market close on Thursday, November 1, 2018. The Company’s management will host a conference call at 4:30 p.m. ET that same day to discuss the results. To participate in the conference call, dial 844-889-7792 (domestic) or 661-378-9936 (international) and refer to the passcode 3386328. This conference call will also be webcast an

 

Multiple Myeloma Experts, Patients, Advocates and Caregivers Team Up to Hike Mount Everest Base CampOpen in a New Window

CRANBURY, N.J.--(BUSINESS WIRE)--Multiple Myeloma Experts, Patients, Advocates and Caregivers Team Up to Hike Mount Everest Base Camp

 

Americans Urged to Get Flu Shots Following Record-Breaking Flu SeasonOpen in a New Window

PHILADELPHIA--(BUSINESS WIRE)--#AmeriHealthCaritas--AmeriHealth Caritas urges Americans to get flu shots as flu season begins.

 

Castle Biosciences Announces Medicare Coverage for the DecisionDx-Melanoma Test in Cutaneous MelanomaOpen in a New Window

FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc., the skin cancer diagnostics company providing molecular diagnostics to improve cancer management decisions, today announced Medicare coverage for the DecisionDx®-Melanoma test that predicts risk of metastatic disease and helps to guide use of sentinel lymph node biopsy (SLNB) in patients with cutaneous melanoma. "Improved access to the DecisionDx-Melanoma test for the 59 million Medicare recipients can drive better-informed manageme

 

Study Shows Decrease in Misuse of OTC Acetaminophen-Containing Combination ProductsOpen in a New Window

WASHINGTON--(BUSINESS WIRE)--In a study newly published in the medical journal Clinical Toxicology, “therapeutic misuse” of over-the-counter (OTC) combination products containing acetaminophen was infrequent and declined over a 10-year period (from 2007-2016). Researchers used the National Poison Data System (NPDS) to identify therapeutic misuse – when someone exceeds the maximum dose of an ingredient while using it for its intended purpose – involving acetaminophen-containing combination produ

 

Battelle’s Doubles Havant Lab Space to Accommodate Expansion of Agrochemical Formulation BusinessOpen in a New Window

HAVANT, England--(BUSINESS WIRE)--Battelle has expanded its specialized agrochemical formulation development laboratory in Havant, England. “This expansion allows us to significantly increase our laboratory capacity and demonstrates our commitment to provide independent services to the agrochemical industry in this niche area,” said Mike Janus, Vice President and General Manager of Battelle’s Environment and Infrastructure business. “Battelle is a world leader in the field of agrochemical formu

 

Fabric Genomics and Genomenon Sign Partnership Agreement to Speed Genomic InterpretationOpen in a New Window

OAKLAND, Calif. & ANN ARBOR, Mich.--(BUSINESS WIRE)--Fabric Genomics™ and Genomenon® announces partnership with goal of further strengthening clinical genomic interpretation and variant classification.

 

Onxeo to Present Overview of AsiDNA™ for Treatment of Solid Tumors at DNA Damage Response Therapeutics Summit 2019Open in a New Window

PARIS--(BUSINESS WIRE)--Regulatory News: Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a clinical-stage biotechnology company specializing in the development of innovative drugs in oncology, targeting tumor DNA Damage Response (DDR) to fight resistant cancers, today announced that the Company was invited to present an overview of AsiDNA™ for the treatment of solid tumors at the 2nd DNA Damage Response Therapeutics Summit (DDRTS) to be held January 29-31, 2019, in Boston, M

 

2014 Giants of Cancer Care® Inductee James P. Allison, Ph.D., Awarded the 2018 Nobel Prize in Physiology or MedicineOpen in a New Window

CRANBURY, N.J.--(BUSINESS WIRE)--2014 Giants of Cancer Care® Inductee James P. Allison, Ph.D., Awarded the 2018 Nobel Prize in Physiology or Medicine

 

Vertex Data Presented at North American Cystic Fibrosis Conference (NACFC) Demonstrate Rapid Progress Toward Expanding and Enhancing Options for Treating the Underlying Cause of Cystic FibrosisOpen in a New Window

DENVER--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that eight scientific abstracts from the company’s portfolio of cystic fibrosis (CF) medicines are being presented at the 32nd North American Cystic Fibrosis Conference taking place October 18-20, 2018 in Denver. Key highlights include presentations of Phase 2 data evaluating clinical safety and efficacy as well as in vitro data of two triple combination regimens (VX-659, tezacaftor and ivacaftor; VX-445

 

TransEnterix CEO, Todd Pope Named One of TIME Magazine’s 50 Most Influential People in Health Care 2018Open in a New Window

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--TransEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between surgeons and patients to improve minimally invasive surgery, congratulates its President and Chief Executive Officer, Todd M. Pope, for being named to TIME Magazine's 50 Most Influential People in Health Care for 2018. In this inaugural list, Pope is highlighted for his role as one of those leaders whose work right now is transforming health c

 

New Studies Support Exactech Technologies at International Scientific ConferenceOpen in a New Window

GAINESVILLE, Fla.--(BUSINESS WIRE)--Exactech, a developer and producer of innovative implants, instrumentation and computer-assisted technologies for joint replacement surgery, announced today that 14 studies involving its knee, hip and shoulder joint replacement innovations and its ExactechGPS® guided personalized surgery system were recently featured at the 31st Congress of The International Society for Technology in Arthroplasty (ISTA) in London, United Kingdom. Studies featuring Exactech te

 

Bigfoot Biomedical® Names Jyoti Palaniappan as Chief Commercial Officer and Ian Hanson as Chief Technology OfficerOpen in a New Window

MILPITAS, Calif.--(BUSINESS WIRE)--#diabetes--Digital drug delivery startup Bigfoot Biomedical has named Jyoti Palaniappan as Chief Commercial Officer and Ian Hanson as Chief Technology Officer.

 

FORTUNE and Great Place to Work® Name Horizon Pharma plc to 2018 Best Small & Medium Workplaces for Third Consecutive YearOpen in a New Window

DUBLIN--(BUSINESS WIRE)--Horizon Pharma has been named one of the 2018 Best Small & Medium Workplaces by FORTUNE and Great Place to Work® for the third consecutive year.

 

Diagnosis of Ovarian Cancer Delayed by Woeful Lack of AwarenessOpen in a New Window

PHILADELPHIA--(BUSINESS WIRE)--The Every Woman Study suggests raising awareness of ovarian cancer could improve outcomes for women.

 

MyndVR Forms National Research Coalition to Study Virtual Reality and the Aging MindOpen in a New Window

DALLAS--(BUSINESS WIRE)--#MyndVR--MyndVR announces the formation of the MyndVR Science Advisory Board and a national research coalition involving universities across the nation.

 

Centric Medical™ Announces 510(k) Clearance of the SATURN™ External Fixation SystemOpen in a New Window

HUNTLEY, Ill.--(BUSINESS WIRE)--Centric Medical, a division of Life Spine®, Inc., which focuses on developing surgical implants for the treatment of lower distal extremity pathology, announced today That the U.S. Food and Drug Administration (FDA) has given 510(k) marketing clearance to the SATURN External Fixation System which consists of rings, struts, threaded rods, pins, wires and connectors intended to be used as a means to stabilize the foot, ankle and long bone segments. “I am excited to

 

MedImpact Selects ExtraHop to Drive Innovation and Improve Customer CareOpen in a New Window

SEATTLE--(BUSINESS WIRE)--#Extrahop--MedImpact Selects ExtraHop to Drive Innovation and Improve Customer Care

 

Verana Health Debuts New Cloud-Based Software Applications to Accelerate Life Science Innovation and Enhance Patient CareOpen in a New Window

SAN FRANCISCO--(BUSINESS WIRE)--Verana Health, the developer of a cutting-edge platform for life science innovation that utilizes regulatory-grade specialty data sets, today announced it will debut several cloud-based software applications that feature near real-time insights for physicians and life science companies at the American Academy of Ophthalmology Annual Meeting 2018 (AAO 2018) in Chicago. These applications apply advanced analytics to information from the American Academy of Ophthalm

 

New Study Finds Gen Z Creates Digital Celebrities Out of Social InfluencersOpen in a New Window

AUSTIN, Texas--(BUSINESS WIRE)--#StateofGenZ--A new national study by The Center for Generational Kinetics found that Gen Z creates digital celebrities out of social media influencers.

 

Cardiac Dimensions Announces DRG Reimbursement Code for Carillon Mitral Contour System in GermanyOpen in a New Window

KIRKLAND, Wash.--(BUSINESS WIRE)--Cardiac Dimensions, a leader in the development of innovative, minimally invasive treatment modalities to address heart failure and related cardiovascular conditions, today announced that InEK, the German Institute for the Hospital Remuneration System, has granted a permanent DRG (Diagnosis Related Group) code covering reimbursement for the company’s Carillon® Mitral Contour System® to treat patients with functional mitral regurgitation (FMR) in Germany. The ne

 

Dexcom G6® Continuous Glucose Monitoring System Will Be Available to Medicare Beneficiaries with Diabetes in Early 2019Open in a New Window

SAN DIEGO--(BUSINESS WIRE)--Dexcom G6® Continuous Glucose Monitoring System Will Be Available to Medicare Beneficiaries with Diabetes in Early 2019

 

Kala Pharmaceuticals to Present at the 2018 American Academy of Ophthalmology (AAO) Annual Meeting and at the Ophthalmology Innovation Summit at AAOOpen in a New Window

WALTHAM, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals announces presentations at the 2018 American Academy of Ophthalmology (AAO) annual meeting and at the Ophthalmology Innovation Summit at AAO

 

LifeScan Partners With gA on Road to IndependenceOpen in a New Window

SAN FRANCISCO--(BUSINESS WIRE)--#LifeScan--gA’s role in executing a rapid, cost effective journey to the Cloud for LifeScan will be featured during Oracle OpenWorld 2018

 

Selexis and Berkeley Lights Collaborate to Accelerate Cell Line Development with the Beacon Optofluidic PlatformOpen in a New Window

GENEVA--(BUSINESS WIRE)--Selexis SA and Berkeley Lights, Inc. today announced a collaboration around the acquisition of Berkeley Lights’ Beacon® optofluidic platform. The partners will leverage the technology to accelerate cell line development (CLD) with the Selexis SUREtechnology Platform™. Selexis scientists have extensively evaluated the Beacon technology and will now further incorporate it into the SUREtechnology Platform workflow. Utilizing the Beacon’s optofluidic and single cell analysi

 

Formativ Health Partners with Conversa to Improve Patient-Provider Access and Clinically Intelligent ConversationsOpen in a New Window

NEW YORK--(BUSINESS WIRE)--#FormativEnhancesPEP--FORMATIV HEALTH PARTNERS WITH CONVERSA TO IMPROVE PATIENT-PROVIDER ACCESS AND CLINICALLY-INTELLIGENT CONVERSATIONS

 

Want to Add a ‘Spring’ to Your Stride? For the First Time, Scientists Have Developed an Unpowered Exoskeleton that Reduces Metabolic Rate While RunningOpen in a New Window

PISCATAWAY, N.J.--(BUSINESS WIRE)--For the first time, scientists have developed an unpowered exoskeleton that reduces metabolic rate while running.

 

Clinipace's Growth Supported by New Executive Leadership and Investment in Clinical TechnologyOpen in a New Window

MORRISVILLE, N.C.--(BUSINESS WIRE)--Clinipace has named John Cargill as its chief commercial officer and Hampton Corley as vice president, business development, clinical analytics.

 

LabCorp and Baptist Health Extend Relationship to Create Comprehensive Laboratory CollaborationOpen in a New Window

BURLINGTON, N.C. & LOUISVILLE, Ky.--(BUSINESS WIRE)--LabCorp® (NYSE: LH) and Baptist Health have entered into a multi-year, comprehensive laboratory collaboration. LabCorp Diagnostics will provide technical services for Baptist Health’s eight hospital-based labs and access to enhanced information technology and data analytics to help improve the delivery of patient care. The new agreement builds upon and deepens an established relationship of more than five years. LabCorp has provided reference

 

Daniel Kolk, Ph.D., Joins XCR Diagnostics, Inc.Open in a New Window

SALT LAKE CITY--(BUSINESS WIRE)--XCR Diagnostics, Inc. announces the appointment of Daniel Kolk, Ph.D., as the company's Vice President of Clinical Development.

 

NeuroBo Pharmaceuticals Announces the Clinical Advancement of Novel Therapies That Address Neurodegenerative Diseases Affecting Millions of Patients GloballyOpen in a New Window

BOSTON--(BUSINESS WIRE)--NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company developing proprietary natural product-based therapeutics for neurodegenerative complications originally developed by Dong-A ST, a major Korean pharmaceutical company, today announced its official launch, marking the start of its efforts in developing treatments for significant unmet patient needs including diabetic neuropathic pain and Alzheimer’s disease. The company is led by John L. Brooks III, a

 

Novocure Announces that the Medicare DME MACs Have Accepted the Local Coverage Determination Reconsideration Request for Optune®Open in a New Window

ST. HELIER, Jersey--(BUSINESS WIRE)--$NVCR #btsm--Novocure announced today that the Medicare DME MACs have accepted the local coverage determination reconsideration request for Optune®.

 

Rocket Pharmaceuticals Presents Updated Long-Term Phase 1/2 Clinical Data of RP-L102 in Fanconi Anemia Patients at the 2018 Annual Congress of the European Society of Gene and Cell Therapy (ESGCT)Open in a New Window

NEW YORK--(BUSINESS WIRE)--Rocket Pharmaceuticals presents updated long-term clinical data from its ongoing Phase 1/2 clinical trial of RP-L102 for FA at ESGCT.

 

RTI Surgical® Schedules Third Quarter 2018 Earnings Call for November 1, 2018Open in a New Window

ALACHUA, Fla.--(BUSINESS WIRE)--RTI Surgical, Inc. announced that it plans to release financial results from the third quarter of 2018 on Thursday, November 1.

 

Pace International Launches New Edible Fruit CoatingOpen in a New Window

WAPATO, Wash.--(BUSINESS WIRE)--PrimaFresh 606 GL

 

Spectrum Pharmaceuticals Announces Dr. Francois Lebel as Chief Medical OfficerOpen in a New Window

HENDERSON, Nev.--(BUSINESS WIRE)--Spectrum Pharmaceuticals Announces Dr. Francois Lebel as Chief Medical Officer

 

Merck’s KEYTRUDA® (pembrolizumab) in Combination with Pfizer’s Inlyta® (axitinib) Significantly Improved Overall Survival (OS) and Progression-free Survival (PFS) as First-Line Therapy for Advanced or Metastatic Renal Cell CarcinomaOpen in a New Window

KENILWORTH, N.J.--(BUSINESS WIRE)--$MRK #MRK--KEYTRUDA in Combination with Pfizer’s Inlyta® Significantly Improved Overall Survival and Progression-free Survival in First Line Advanced RCC

 

Teleflex Announces Third Quarter 2018 Earnings Conference Call InformationOpen in a New Window

WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Announces Third Quarter 2018 Earnings Conference Call Information

 

BioVaxys Selected to Present its Universal Vaccine Platform for Individualized Cancer Therapy at the 2018 BIO Investor ForumOpen in a New Window

SAN FRANCISCO--(BUSINESS WIRE)--BioVaxys LLC (www.biovaxys.com), a clinical-stage immune-oncology company developing a universal vaccine platform for individualized cancer therapy, has been selected to present at the 17th Annual BIO Investor Forum, being held October 17-18, 2018, at the Westin St. Francis in San Francisco, CA. Kenneth Kovan, one of the founders of BioVaxys, will discuss the company’s strategy and its outlook for the future, including its recent patent filings and clinical devel

 

Innovus Pharma Announces Planned Expansion into CBD Oil-Based Products MarketOpen in a New Window

SAN DIEGO--(BUSINESS WIRE)--Innovus Pharmaceuticals, Inc. (“Innovus Pharma” or the “Company”) (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women's health and respiratory diseases, today announced that it plans to expand its product line into the hemp-derived CBD (“Cannabinoid”) oil-based products market beginning in the fourth quarter 2018 w

 

Rodin Therapeutics Launches Clinical Trial of Neuroimaging Tool for Measurement of Synaptic DensityOpen in a New Window

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Rodin Therapeutics launched a clinical trial to assess the performance of a new PET ligand that can measure synaptic density in the living brain.

 

VISEON, Inc. Announces FDA Clearance of the Voyant System for Minimally Invasive Spine Surgery Access, Visualization, and IlluminationOpen in a New Window

IRVINE, Calif.--(BUSINESS WIRE)--Viseon, Inc. today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for their Voyant System for Minimally Invasive Spine Surgery, featuring proprietary HD imaging sensor and illumination technology. The Voyant System is composed of a sterile single-use, disposable retractor device with integrated state-of-the-art visualization technology, and a reusable controller enabling digital intraoperative manipulation of the

 

Covance and Definiens Collaborate to Integrate Digital Pathology into Precision Medicine Design and DevelopmentOpen in a New Window

BURLINGTON, N.C. & MUNICH--(BUSINESS WIRE)--LabCorp® (NYSE: LH), a leading global life sciences company, and Definiens®, a pioneer in artificial intelligence (AI) based image analysis, announced a strategic collaboration to improve global development of precision medicine. The collaboration, between Definiens and LabCorp’s Covance drug development business, will enable seamless integration of digital pathology with clinical-trial design and tissue-based testing solutions, resulting in a faster

 

Cigalah Medpharm Announces the Launch in Saudi Arabia and United Arab Emirates of Nexodyn® AOS, the Tehclo-Based Wound Cleanser Developed by the Swiss Pharma Company APROpen in a New Window

DUBAI, United Arab Emirates & BALERNA, Switzerland--(BUSINESS WIRE)--Nexodyn® AOS, the Tehclo®-based Cleanser for acute and chronic wound management by APR Applied Pharma Research, arrives in Saudi Arabia and UAE.

 

AELIX Therapeutics and Gilead Sciences Enter into a Clinical Research Collaboration Agreement to Evaluate a Therapeutic Vaccine and TLR7 Agonist Regimen for HIV CureOpen in a New Window

BARCELONA, Spain--(BUSINESS WIRE)--AELIX Therapeutics and Gilead Sciences Enter into a Clinical Research Collaboration Agreement for HIV Cure

 

About BioFlorida

BioFlorida represents nearly 6,000 establishments and research organizations in the biopharmaceutical, medical technology and bioagriculture sectors that collectively employ nearly 83,000 Floridians.

 

Members of the BioFlorida network include emerging and established life science companies, universities, research institutions, hospitals, medical centers, incubators, economic development agencies, investors and service providers.

 

Email us for a regional Chapter sponsorship.

Connect